ERRIN Drug Patent Profile
✉ Email this page to a colleague
When do Errin patents expire, and when can generic versions of Errin launch?
Errin is a drug marketed by Dr Reddys Labs Sa and is included in one NDA.
The generic ingredient in ERRIN is norethindrone. There are twenty-six drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the norethindrone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Errin
A generic version of ERRIN was approved as norethindrone by GLENMARK PHARMS LTD on July 22nd, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ERRIN?
- What are the global sales for ERRIN?
- What is Average Wholesale Price for ERRIN?
Summary for ERRIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 76 |
| Patent Applications: | 5,079 |
| Drug Prices: | Drug price information for ERRIN |
| Drug Sales Revenues: | Drug sales revenues for ERRIN |
| DailyMed Link: | ERRIN at DailyMed |
Pharmacology for ERRIN
| Drug Class | Progestin |
US Patents and Regulatory Information for ERRIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dr Reddys Labs Sa | ERRIN | norethindrone | TABLET;ORAL-28 | 076225-001 | Oct 21, 2002 | AB2 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
